GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Retained Earnings

Gyre Therapeutics (Gyre Therapeutics) Retained Earnings : $-85.5 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Gyre Therapeutics's retained earnings for the quarter that ended in Dec. 2023 was $-85.5 Mil.

Gyre Therapeutics's quarterly retained earnings declined from Dec. 2021 ($23.1 Mil) to Dec. 2022 ($7.4 Mil) and declined from Dec. 2022 ($7.4 Mil) to Dec. 2023 ($-85.5 Mil).

Gyre Therapeutics's annual retained earnings declined from Dec. 2021 ($23.1 Mil) to Dec. 2022 ($7.4 Mil) and declined from Dec. 2022 ($7.4 Mil) to Dec. 2023 ($-85.5 Mil).


Gyre Therapeutics Retained Earnings Historical Data

The historical data trend for Gyre Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Retained Earnings Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Retained Earnings
23.08 7.40 -85.54

Gyre Therapeutics Semi-Annual Data
Dec21 Dec22 Dec23
Retained Earnings 23.08 7.40 -85.54

Gyre Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Gyre Therapeutics  (NAS:GYRE) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Gyre Therapeutics (Gyre Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines